Sirolimus monotherapy for Erdheim–Chester disease

References

• Haroche J, Arnaud L, Cohen-Aubart F, et al. Erdheim-Chester disease. Curr Rheumatol Rep. 2014;16:412.
   PubMed Web of Science ®Google Scholar
• Estrada-Veras JI, O’Brien KJ, Boyd LC, et al. The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv. 2017;1:357–366.
   PubMed Web of Science ®Google Scholar
• Hervier B, Arnaud L, Charlotte F, et al. Treatment of Erdheim-Chester disease with long-term high-dose interferon-α. Semin Arthritis Rheum. 2012;41:907–913.
   PubMed Web of Science ®Google Scholar
• Arnaud L, Hervier B, N´eel A, et al. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011;117:2778–2782.
   PubMed Web of Science ®Google Scholar
• Haroche J, Amoura Z, Trad SG, et al. Vaiability I the efficacy of interferon-α in Erdheim-Chester disease by patient and site of involvement. Arthritis Rheum. 2006;54:3330–3336.
   PubMed Web of Science ®Google Scholar
• Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120:2700–2703.
   PubMed Web of Science ®Google Scholar
• Haroche J, Cohen-Aubart F, Emile JF, et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. Jco. 2015;33:411–418.
   PubMed Web of Science ®Google Scholar
• Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol. 2018;4:384–388.
   PubMed Web of Science ®Google Scholar
• Vaglio A, Diamond EL. Erdheim-Chester disease: the "targeted" revolution (editorial). Blood. 2017;130:1282–1284.
   PubMed Web of Science ®Google Scholar
• Powell JD, Pollizzi KN, Heikamp EB, et al. Regulation of immune responses by mTOR. Annu Rev Immunol. 2012;30:39–68.
   PubMed Web of Science ®Google Scholar
• Yuan R, Kay A, Berg WJ, et al. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol. 2009;2:45.
   PubMed Web of Science ®Google Scholar
• Perl A. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat Rev Rheumatol. 2016;12:169–182.
   PubMed Web of Science ®Google Scholar
• McCormack FX, Inoue Y, Moss J, National Institutes of Health Rare Lung DiseasesConsortium; MILES Trial Group, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364:1595–1606.
   PubMed Web of Science ®Google Scholar
• Gianfreda D, Nicastro M, Galetti M, et al. Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial. Blood. 2015;126:1163–1171.
   PubMed Web of Science ®Google Scholar
• Haroche J, Amoura Z. mTOR: a new target in Erdheim-Chester disease?. Blood. 2015;126:1151–1152.
   PubMed Web of Science ®Google Scholar
• Goyal G, Shah MV, Call TG, et al. Efficacy of biological agents in the treatment of Erdheim-Chester disease. Br J Haematol. 2018;183:520–524.
   PubMed Web of Science ®Google Scholar
• Graziani G, Podestà MA, Cucchiari D, et al. Erdheim-Chester disease: from palliative care to targeted treatment. Clin Kidney J. 2014;7:339–343.
   PubMedGoogle Scholar
• Ventura-Aguiar P, Campistol JM, Diekmann F. Safety of mTOR inhibitors in adult solid organ transplantation. Exp Opin Drug Saf. 2016;15:303–319.
   PubMed Web of Science ®Google Scholar
• Sadowski K, Kotulska K, Jóźwiak S. Management of side effects of mTOR inhibitors in tuberous sclerosis patients. Pharmacol Rep. 2016;68:536–542.
   PubMed Web of Science ®Google Scholar
• Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando). 2014;28:126–133.
   PubMedGoogle Scholar
• Hillel AT, Gelbard A. Unleashing rapamycin in fibrosis (editorial). Oncotarget. 2015;6:15722–15723.
   PubMedGoogle Scholar
• Luo L, Zhang C, Zhao J, et al. Effects of rapamycin on reduction of peridural fibrosis: an experimental study. Med Sci Monit. 2015;21:482–488.
   PubMed Web of Science ®Google Scholar
• Wang B, Ding W, Zhang M, et al. Rapamycin attenuates aldosterone-induced tubulointerstitial inflammation and fibrosis. Cell Physiol Biochem. 2015;35:116–125.
   PubMed Web of Science ®Google Scholar
• Emile JF, Diamond EL, H´elias-Rodzewicz Z, et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood. 2014;124:3016–3019.
   PubMed Web of Science ®Google Scholar